IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
about
Immunotherapy for advanced renal cell cancerImmunotherapy for advanced renal cell cancerSunitinib in the treatment of metastatic renal cell carcinomaImmunotherapy for metastatic renal cell carcinoma.Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DImmunotherapy of metastatic renal cell cancer.Evolving immunotherapeutic strategies in bladder and renal cancerTherapeutic approaches in metastatic renal cell carcinoma.Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma.Immunotherapy options in metastatic renal cell cancer: where we are and where we are going.IPM chemotherapy in cytokine refractory renal cell cancer.Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinomaCurrent status of cytokine therapy in management of patients with metastatic renal cell carcinoma.Establishing the role of cytokine therapy in advanced renal cell carcinoma.Adjuvant therapy in renal cell carcinoma-past, present, and future.Immunotherapy for renal cell cancer in the era of targeted therapy.Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline.Metastatic renal carcinoma comprehensive prognostic systemAlternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs.Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.Role of cytokine therapy for renal cell carcinoma in the era of targeted agents.Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.Different responses to two types of 5-fluorouracil prodrugs in combination with interferon-alpha in pulmonary metastases of renal cell carcinoma: a case report.Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.Treatment of renal cell carcinoma: Current status and future directions.Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.Metastatic renal cell carcinoma presenting in the external auditory canal.An update on current management of advanced renal cell cancer, biomarkers, and future directionsIs there a role for adjuvant therapy after surgery in “high risk for recurrence” kidney cancer? An update on current concepts
P2860
Q24187300-A0B5DC85-6DB1-4EAF-A8F9-292D8CCB31C5Q24246777-4A7F2707-EBB9-4744-8016-BE59A2364986Q28072057-23603C93-F9F4-4329-B244-AC0D89162F2FQ30234458-DB10551A-C16E-423A-B59B-3BE3EC4DCD8DQ33716744-2158E71A-D22B-4687-B0ED-C8CCDF95D939Q34555854-CE50547A-BC28-44D6-B936-BA8FD2771037Q34849167-C5E7F41D-DB1F-44B4-ADBD-5F9E43B139B9Q35519671-B96569C5-231F-45AA-B5CF-DF28BE827BD3Q36118589-56124FC5-5182-4187-A753-E9AFAE77804CQ36612231-13196D1B-A7F9-42E0-B554-889C1FC3BCC1Q36636648-A2C66F06-712D-4BD1-9F63-C6F0B8E9ADE9Q36636651-16DB7909-A596-46E7-8848-0C1190A5E4ABQ36648893-B3553293-4ADD-4BCA-9844-2F41EC5BFDFCQ36696255-9A711DE8-5A81-4A36-9C6C-8EA1B943DEDEQ36710382-E78D8A3F-2F90-43A0-96D6-506481D00B7FQ37086157-B7FF8ACD-4E0A-436B-9C51-600B7CBCA8DDQ37153437-A4B1D4F3-F008-413C-B2B8-41AA1D147BC6Q37183451-39E9C0F6-DFE0-4835-B4A4-17A91AA6723FQ37187448-38A4EAB6-DCFD-4066-AB9A-0436C8BA79D2Q37354998-4F521D10-4D38-4ABA-A403-68D98EE34615Q37418672-B84CA3D8-35AE-4F87-850B-471D683E1582Q38233353-C88ABBD4-9967-4C37-A96A-9FD6259BE38CQ41895084-D0197827-27D4-4DB7-8D13-3DF8F3D09D57Q41898172-8F1F6696-087C-4290-A67B-42A9E03AC1C5Q42549684-2CE04C97-E2A3-43B4-BE1F-03ACEE870573Q44124135-8221B6C7-4E5C-4B99-8244-AC690851A993Q44954461-5A754831-1292-4E6F-8647-42E39318BC64Q47726014-43C47977-D26D-408F-9C39-45F5229F6729Q51112501-0D463FF4-D139-48E2-BB9A-69940338CB0AQ53559604-A8C90800-B812-41DE-A0BE-07825D89F5E4Q56897121-574829EB-E76A-4E7B-84B9-03ED35C1A945Q59126184-61646702-495D-49DF-954B-A96A8736504B
P2860
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
IL-2 in combination with IFN- ...... lled randomized clinical trial
@ast
IL-2 in combination with IFN- ...... lled randomized clinical trial
@en
IL-2 in combination with IFN- ...... lled randomized clinical trial
@nl
type
label
IL-2 in combination with IFN- ...... lled randomized clinical trial
@ast
IL-2 in combination with IFN- ...... lled randomized clinical trial
@en
IL-2 in combination with IFN- ...... lled randomized clinical trial
@nl
prefLabel
IL-2 in combination with IFN- ...... lled randomized clinical trial
@ast
IL-2 in combination with IFN- ...... lled randomized clinical trial
@en
IL-2 in combination with IFN- ...... lled randomized clinical trial
@nl
P2093
P2860
P356
P1476
IL-2 in combination with IFN- ...... lled randomized clinical trial
@en
P2093
H J Illiger
H Kirchner
J Atzpodien
M Gramatzki
S Jürgenson
P2860
P2888
P304
P356
10.1054/BJOC.2001.2076
P407
P577
2001-10-19T00:00:00Z
P5875
P6179
1037245726